What Researchers Did
Researchers reviewed the biology and clinical importance of hypoxia in head and neck cancer, incorporating literature and their own experience with hypoxia measurements.
What They Found
They found that hypoxia is present in most head and neck cancers and consistently acts as a negative prognostic factor, increasing resistance to radiation and cytotoxic drugs and promoting malignant progression. Clinical trials have shown some success with methods to overcome hypoxia, such as radiosensitizers like nimorazole, hypoxic cytotoxins like tirapazamine, and carbogen.
What This Means for Canadian Patients
For Canadian patients with head and neck cancer, tumor hypoxia may indicate a more aggressive disease that is harder to treat with standard therapies. Ongoing research into strategies like radiosensitizers and hypoxic cytotoxins offers potential future avenues for improving treatment outcomes.
Canadian Relevance
This review article has no direct Canadian connection.
Study Limitations
A key limitation is the lack of a "gold standard" for measuring hypoxia, with current methods having disadvantages and reliable clinical methods for distinguishing different forms of hypoxia still missing.